United Therapeutics Corporation products

Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).

The most widely recognized method of removing cells in use today is “immersion decellularization” in which a tissue or organ is soaked in strong detergent which diffuses from the outer surface inward, and then back out once the cells are dissolved which is limited to a few millimeters.  The end result is a partially degraded scaffold with a compromised vascular network and an outer organ capsule that will not maintain physiological pressures when tested. In addition, cells no longer recognize this degraded scaffold as the appropriate environment in which to become functional.

Perfusion recellularization begins with organ scaffolds created by perfusion decellularization. These scaffolds are capable of receiving and incorporating a variety of cell types, depending on the organ scaffold utilized. Perfusion decellularization enables organ scaffolds to retain their native vasculature and so cells are introduced through existing vascular pathways.

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH; WHO Group 1), to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

Miromatrix is developing bioengineered organs for transplantation, and our technology can be applied across the spectrum of donor needs. We are currently focused on bioengineering transplantable kidneys (MiroKidney) and livers (MiroLiver), but we believe our technology can be used to engineer other in-demand organs, such as lungs, pancreases, hearts and other internal organs or vascularized tissues. 

TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.

Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.